Format

Send to

Choose Destination
JACC Heart Fail. 2014 Dec;2(6):663-70. doi: 10.1016/j.jchf.2014.09.001. Epub 2014 Oct 8.

Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.

Author information

1
Department of Pharmacy, University of Wisconsin School of Pharmacy, Madison, Wisconsin. Electronic address: orly.vardeny@wisc.edu.
2
Department of Pharmacy, University of Wisconsin School of Pharmacy, Madison, Wisconsin.
3
Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Abstract

Neprilysin is an enzyme that contributes to the breakdown of the biologically active natriuretic peptides and several other vasoactive compounds. Inhibiting neprilysin has been a therapeutic target for several compounds that have been tested in cardiovascular disease, including ecadotril, candoxatril, omapatrilat, and LCZ696. Although ecadotril, candoxatril, and omapatrilat were initially tested in hypertension and/or heart failure, lack of efficacy and side effects led to discontinuation of their development. LCZ696 (sacubitril valsartan) is a first-in-class angiotensin receptor neprilysin inhibitor that has been developed for use in heart failure. This compound is composed of 2 molecular moieties in a single crystalline complex-the angiotensin receptor blocker valsartan and a neprilysin inhibitor prodrug-and has now been tested in hypertension, in a phase 2 trial in heart failure with preserved ejection fraction, and has demonstrated greater efficacy than enalapril in a phase 3 trial in heart failure with reduced ejection fraction. Its ability to inhibit the renin-angiotensin-aldosterone axis and augment the endogenous natriuretic peptide system provides a distinctive mechanism of action in cardiovascular disease.

KEYWORDS:

heart failure; natriuretic peptide; neprilysin

PMID:
25306450
DOI:
10.1016/j.jchf.2014.09.001
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center